ERT | Jotup

AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease

Retrieved on:

Thursday, October 27, 2022

Health, FDA, Stem Cells, Genetics, Other Health, General Health, Clinical Trials, U.S. Securities and Exchange Commission, Spleen, Growth, Phrase, ERT, Macrophage, Hunter syndrome, Central nervous system, Stem cell, Private Securities Litigation Reform Act, Bone marrow, Cell, BLA, Glycogen storage disease type II, Enzyme replacement therapy, NDA, Outline, New Drug Application, Glycogen storage disease, Industry, COVID-19, Health, Mortality, Compte rendu, Clinical trial, FDA, Patient, LinkedIn, Quality of life, AVRO, Fatigue, Biologics license application, Nasdaq, Parkinson's disease, Data collection, Gaucher's disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Risk, Liver, Food, Cystinosis, Security (finance), Life expectancy, Lists of diseases, Twitter, Safety, Pharmaceutical industry, Gaucher

FDAs Rare Pediatric Disease Designation and Voucher Program is intended to facilitate the development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.

Key Points:

FDAs Rare Pediatric Disease Designation and Voucher Program is intended to facilitate the development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
AVROBIOs Gaucher disease program includes Gaucher disease type 1 and type 3, which collectively impact an estimated 30,000 patients worldwide.
Gaucher disease is a rare, inherited lysosomal disorder characterized by the toxic accumulation of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in macrophages.
Our first-in-class pipeline includes clinical programs for cystinosis and Gaucher disease type 1, as well as preclinical programs for Gaucher disease type 3, Hunter syndrome and Pompe disease.

Eternal Rock Token (ERT) Is Now Available for Trading on LBank Exchange

Retrieved on:

Tuesday, October 18, 2022

Internet City, Dubai--(Newsfile Corp. - October 18, 2022) - LBank Exchange, a global digital asset trading platform, has listed Eternal Rock Token (ERT) on October 17, 2022.

Key Points:

Internet City, Dubai--(Newsfile Corp. - October 18, 2022) - LBank Exchange, a global digital asset trading platform, has listed Eternal Rock Token (ERT) on October 17, 2022.
For all users of LBank Exchange, the ERT/USDT trading pair is now officially available for trading.
Its native token Eternal Rock Token (ERT) has been listed on LBank Exchange at 13:00 UTC on October 17, 2022, to further expand its global reach and help it achieve its vision.
NEO FANTASY implements a multi-tokenomic system consisting of a primary governance token ERT (ETERNAL ROCK TOKEN) and an in-game utility token FTS (FANTASY).

AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease

Retrieved on:

Tuesday, October 18, 2022

General Health, Health, Genetics, Stem Cells, Clinical Trials, LinkedIn, Data collection, AVRO, Mortality, Bone marrow, Innovation, Health, ERT, National Institute for Health and Care Excellence, Stem cell, Cystinosis, Phrase, Quality of life, Compte rendu, Risk assessment, Spleen, Twitter, Private Securities Litigation Reform Act, Industry, Enzyme replacement therapy, Healthcare Improvement Scotland, Clinical trial, Central nervous system, National Institute, NHS, Risk, Glycogen storage disease type II, Health care, Macrophage, MHRA, Growth, Glycogen storage disease, Frexit, Parkinson's disease, Security (finance), Cell, Hunter syndrome, Lists of diseases, Outline, Life expectancy, MAA, Marketing, Fatigue, SMC, Patient, Nasdaq, Gaucher's disease, Liver, Safety, NICE, National Health Service, COVID-19, Pharmaceutical industry, Gaucher

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K.

Key Points:

(Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the U.K.
Gaucher disease is a rare, inherited lysosomal disorder characterized by the toxic accumulation of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in macrophages.
Our first-in-class pipeline includes clinical programs for cystinosis and Gaucher disease type 1, as well as preclinical programs for Gaucher disease type 3, Hunter syndrome and Pompe disease.
Our proprietary plato gene therapy platform is designed to be scaled to support late-stage clinical development and commercialization globally.

Radware Selected by Bilfinger for DDoS Protection Services

Retrieved on:

Wednesday, October 12, 2022

MAHWAH, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Radware (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, announced that German industrial services provider Bilfinger SE has chosen Radwares DefensePro DDoS Protection and Cloud DDoS Protection Service to increase cyber defenses across its global hybrid IT infrastructure.

Key Points:

MAHWAH, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Radware (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, announced that German industrial services provider Bilfinger SE has chosen Radwares DefensePro DDoS Protection and Cloud DDoS Protection Service to increase cyber defenses across its global hybrid IT infrastructure.
One of the reasons we selected Radware was because of the flexibility and combined strength of its state-of-the-art DDoS protection solutions, said Andreas Pfau, head of Bilfingers CIO office.
Together, they offer low latency and uninterrupted protection while delivering the high capacity required to mitigate sophisticated, large-scale volumetric DDoS attacks.
For network security, Bilfinger deployed Radware's DefensePro DDoS Protection and Cloud DDoS Protection Service.

Fabry Disease Market to Boost at a CAGR of 7.65% by 2032 | DelveInsight

Retrieved on:

Tuesday, October 4, 2022

DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points:

DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
The increasing prevalence of the disease, along with the promising emerging pipeline therapies with new mechanisms of action, will fuel the Fabry disease market during the forecast period.
In the European and Japanese Fabry disease treatment market, Replagal (Takeda/Shire), Fabrazyme (Sanofi-Genzyme), and Galafold (Amicus Therapeutics) are currently the only approved therapies for Fabry disease patients.
To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market

Fabry Disease Market to Boost at a CAGR of 7.65% by 2032 | DelveInsight

Retrieved on:

Tuesday, October 4, 2022

DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points:

DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
The increasing prevalence of the disease, along with the promising emerging pipeline therapies with new mechanisms of action, will fuel the Fabry disease market during the forecast period.
In the European and Japanese Fabry disease treatment market, Replagal (Takeda/Shire), Fabrazyme (Sanofi-Genzyme), and Galafold (Amicus Therapeutics) are currently the only approved therapies for Fabry disease patients.
To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market

LOWE'S PLEDGES $2 MILLION TO SUPPORT HURRICANE IAN RELIEF EFFORTS

Retrieved on:

Friday, September 30, 2022

Emergency shelter, Safety, NYSE, Emergency, Organization, Company, Lowe's, Meal, Lowe, Tropical Storm Ian, Incident response team, CEO, ERT, Food, Newsroom, Bottled water

MOORESVILLE, N.C., Sept. 30, 2022 /PRNewswire/ -- Lowe's today announced it will donate $2 million to support relief efforts in Florida after Hurricane Ian left devastation across the state, causing catastrophic flooding and damage. Lowe's donation will support disaster relief partners and nonprofit Pro customers, helping organizations provide emergency shelter, food and rebuilding supplies to those affected by the storm. Lowe's also will host relief events to distribute critical supplies.

Key Points:

MOORESVILLE, N.C., Sept. 30, 2022 /PRNewswire/ -- Lowe's today announced it will donate $2 million to support relief efforts in Florida after Hurricane Ian left devastation across the state, causing catastrophic flooding and damage.
Lowe's donation will support disaster relief partners and nonprofit Pro customers, helping organizations provide emergency shelter, food and rebuilding supplies to those affected by the storm.
"It's heartbreaking to see the devastation and the impact on our customers and associates who have been affected by this storm.
In immediate response to Hurricane Ian, Lowe's stores in the hardest-hit areas will host bucket brigade events to distribute free cleanup supplies to residents who are continuing recovery efforts.

ILUS Confirms Share Lock-Up Opportunity

Retrieved on:

Thursday, September 29, 2022

Time, Sale, Lock, Shareholder, Share (finance), Growth, OTC, ERT, Leak, Documentation, Â, GLOBE, Mergers and acquisitions, Management, Security (finance)

NEW YORK, NY, Sept. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ILUS International Inc (OTC: ILUS) is a Mergers and Acquisitions company focused on acquiring and growing public safety and industrial companies across the globe.

Key Points:

NEW YORK, NY, Sept. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ILUS International Inc (OTC: ILUS) is a Mergers and Acquisitions company focused on acquiring and growing public safety and industrial companies across the globe.
In line with this progress and in an effort to create maximum value for its long-term shareholders, ILUS will be providing its shareholders with an opportunity to lock-up ILUS shares in a preference category as follows:
Participating Shareholders may receive a consideration percentage in ILUS shares which offers the opportunity for these shares to be converted for shares in Emergency Response Technologies (ERT) or any other ILUS subsidiary where legally possible.
As planned, our business is now taking multiple giant leaps forward and shareholders who continue on this journey with us for the longer-term will have the opportunity to obtain maximum value.
For further information on the companies please see the ILUS communication channels.

Electronic Clinical Outcome Assessment Solutions Global Market Report 2022: Increase in Research and Development Activities Drives Sector Growth - ResearchAndMarkets.com

Retrieved on:

Thursday, September 29, 2022

The regions covered in the electronic clinical outcome assessment solutions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Key Points:

The regions covered in the electronic clinical outcome assessment solutions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
An increase in research and development activities is expected to propel the growth of the electronic clinical outcome assessment solutions market going forward.
Electronic clinical outcome assessment solutions help research and development activities by capturing outcomes data electronically in clinical trials.
Therefore, an increase in research and development activities is driving the electronic clinical outcome assessment solutions market.

DNAnexus Appoints Chief Commercial Officer to Accelerate Global Adoption of Leading Biomedical Data-Driven Technology Platform

Retrieved on:

Tuesday, September 20, 2022

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the appointment of Stephen Nuckols as Chief Commercial Officer.

Key Points:

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the appointment of Stephen Nuckols as Chief Commercial Officer.
Steve brings decades of valuable industry experience managing cross-functional teams and scaling commercial operations for leading software companies, said Richard Daly, CEO at DNAnexus.
He previously served as ArisGlobals Chief Revenue Officer, where he was responsible for leading all aspects of the commercial organization.
Prior to ArisGlobal, he served as Executive Vice President and Chief Commercial Officer at ERT, a leading data and technology company supporting clinical drug development companies.